wellrank.ai

Wegovy vs Zepbound: which one should I ask for and where do I get either online?

ClaudecomparisonCollected Jun 20, 2026, 13:08 UTC

Verbatim response from Claude

Wegovy vs Zepbound: Quick Comparison

The Drugs

Wegovy (semaglutide)

  • GLP-1 receptor agonist
  • ~15% average body weight loss in trials
  • Made by Novo Nordisk
  • Weekly injection

Zepbound (tirzepatide)

  • Dual GIP/GLP-1 receptor agonist
  • ~20-22% average body weight loss in trials
  • Made by Eli Lilly
  • Weekly injection

Which to Ask For?

Zepbound has the edge for most people because:

  • Stronger average weight loss in head-to-head data
  • Often more affordable with Lilly's savings card (~$550/month or less with insurance)
  • Newer but well-studied

Consider Wegovy if:

  • You have cardiovascular disease (it has an FDA-approved CV benefit indication)
  • Your insurance covers it but not Zepbound

Where to Get Either Online

  • Hims & Hers – easy telehealth access, though often offers compounded versions
  • Ro Body – straightforward process, good support
  • Lilly Direct – gets you actual branded Zepbound directly
  • Found or Calibrate – include coaching programs

⚠️ Important Notes

  • Require a prescription from a licensed provider
  • Avoid unverified online pharmacies selling compounded versions without oversight

Talk to your doctor about your specific health history first!

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.